Key Takeaways
- Margin reset, recovery promised: EBITDA margin compressed ~650 bps ex-forex over nine months, but management guided to ~21% EBITDA margin in FY24 and expects margins to rise ~1% annually for the next three years thereafter.
- API business troughing: API revenue declined ~7% over nine months as high-cost KSM inventory, lower prices, and impurity testing issues compressed margins; management expects normalization from Q1 FY24 and a doubling of the API business over time.
- Domestic formulation resilient, chronic weak: Domestic formulations grew 9% in Q3, led by pain management at 15%, while Cardiovascular and Anti-diabetic growth slumped to ~2% for the quarter on unprecedented market softness.
- Dewas plant is a pure cost drag with zero revenue: All costs (depreciation, people, testing, energy) are hitting the P&L while the plant operates in validation mode; filings are expected to begin early next year, with inspections and approvals to follow.
- What to watch next quarter: Whether the guided Q4 revenue growth of 10–12% materializes, the pace of API margin recovery as high-cost KSM inventory clears, and any update on US FDA re-inspection scheduling for the remediated sites.
Margin Walk: What Compressed, What Recovers
- Material cost spike: Q3 material cost ratio rose to 34.13% from 32.46% YoY, driven by higher input costs (solvents, aluminum foil), China COVID disruptions, and the conversion of higher-cost KSM into API sold at lower prices.
- Manufacturing expense surge: Manufacturing expenses rose ~13% against ~9–10% overall growth, with power tariffs increasing after a two-year COVID freeze and energy costs up ~45% on high coal and furnace oil prices.
- Promotional spend jump: Promotional costs rose 40–45% YoY as post-COVID activity resumed and ~1,500 medical representatives were added; management expects these costs to stay flat next year, creating operating leverage as revenue grows.
- Dewas plant cost drag: All costs of the Dewas plant (depreciation, people, testing, energy) are debited to the P&L with no top-line contribution, as the plant is in validation mode; this is a one-time, 1–1.5-year industry-wide pain.
- Artemisinin margin squeeze: API gross margins were hit because annual contracts were signed at higher prices during the agri season; when open-market artemisinin prices subsequently fell, API sales had to be priced at lower current market prices, compressing margins.
- Sartan inventory overhang: Sartan inventories were stuck at much higher procurement prices (e.g., $9, double the earlier rate) due to six-to-eight-month delays from impurity issues and approvals; those high-cost inventories are now being disposed of.
- Forex losses: Overall net forex loss of ~₹41.9 crores YTD, driven by realized loss of ₹6.68 crores and unrealized loss of ₹35.22 crores, arising from forward contracts on outstanding bills; gains on higher realizations were offset by forward and import-side losses.
- Margin recovery bridge to 21%: Gross margins will improve 1–1.5% as KSM prices soften; promotional cost leverage will add ~2%; capacity utilization will rise with business growth; no further MR additions are planned, so only wage inflation will pressure people costs; Dewas may begin contributing revenue mid-year.
Harish Kamath: "Gross margin is not a concern for us. It's a short-term issue."
API Business: The Trough and the Turn
- Nine-month decline: API business declined ~7% over nine months (INR 1,084 cr to INR 1,004 cr) due to lower demand, price reductions, and nitrosamine/azido impurity issues; Q3 showed a tentative recovery with ~4% growth.
- KSM inventory drag: Higher-priced KSM inventory affected results through Q3 end because of the time gap from procurement to utilization; as a backward-integrated manufacturer, KSM inventory in some materials is higher than average. As of the call date, not many high-priced KSMs remain.
- One residual overhang: One particular KSM (Antimalarials) where the average holding price may be around $180 vs. a current market price of ~$140 may have some impact for the next six months; all other inventories will normalize in Q4 or next quarter.
- Impurity testing resolved: Nitrosamine and azido impurity testing issues required revised methods and filings; all that work is now done, and testing has become routine.
- Excess inventories depleting: Excess inventories in developed markets (both API and generics) are now getting depleted, removing a demand headwind.
- Q4 recovery expected: Management expects the 7–8% nine-month decline to be entirely covered in Q4, with the full-year API business more or less at the same number as last year (~INR 1,311 crores).
- FY24 normalization: From Q1 FY24 onwards, everything should be back to normal; gross margin on API business will improve as high-cost inventory is fully cleared and demand picks up.
- Doubling aspiration: Management stated that from here onwards, the API business should double, driven by new products, volume growth in existing products (with significant headroom), and capacity additions; no specific timeframe was given.
Harish Kamath: "See what has happened, actually, whatever KSM we purchased at higher prices, they got converted into API, which got sold at a lower price. So that was going on for last two to three quarters. Maybe some pain will be there in the fourth quarter. But from the next financial year, first quarter onwards, everything should be back to normal."
Domestic Formulations: Market Share Gains, Chronic Slowdown
- Q3 growth led by pain management: Domestic formulations grew 9% in Q3, with Rheumatoid Arthritis and Osteoarthritis at 15% growth; Cardiovasculars and Anti-diabetics were lower at ~2%; Antimalarials continued their decline at ~36% for the quarter.
- Market share and rank improvement: Market share rose from 1.77% in 2021 to 1.86% in 2022; rank improved from 21st to 17th; all five top-300 brands improved their ranks.
- Therapy rank gains: Ipca ranked 13th in Acute (three-rank gain) and 18th in Chronic (one-rank gain); outpaced industry growth in both acute and chronic per IQVIA.
- Chronic market softness: Cardiovascular and Anti-diabetic growth slumped to ~4% over nine months, which management called unprecedented in 15–20 years; possible factors include post-COVID stock normalization (patients keeping six-month to one-year stock during COVID, now buying normally) and mortality among elderly patients who were heavy users of cardiovascular drugs.
- Divisionalization disruption: Two new cardiac divisions were added in the current year, and products were reshuffled, causing market disturbance that contributed to the low 4% growth in Cardio/Diabetes.
- Other therapies strong: CNS +18%, Derma +18%, Ophthalmology +17%, Neuro +13%, Cough and Cold +10% despite a high base; Antibacterials saw a marginal decline (INR 134 cr vs INR 143 cr) despite ~100% growth last year, building a base for future growth.
- NLEM impact manageable: Scheduled Formulations now only 17% of domestic business, down significantly because Antimalarials (mostly Scheduled) declined and NLEM price reductions took effect; the net NLEM impact in FY24 is ~3–3.5% after a ~12% WPI price rise in April, and with only 17% of the portfolio affected, the impact is marginal.
- MR expansion complete: ~1,500 medical representatives have been added, broadly completing the expansion; productivity gains from these additions are expected to contribute to margin improvement next year.
Ajit Kumar: "So post-COVID also, that also may be one of the impact could be there in this market, because we have never seen this kind of growth in Cardiovasculars and Antidiabetics for last 15, 20 years. This market has been significantly moving up. It's only the current year that your market itself has not done that well."
Export Formulations and ROW Markets
- Branded export growth: Export Branded Formulation grew ~17% in Q3 (INR 109 cr to INR 125 cr); nine-month growth ~11%; full year expected at 17–18% with Q4 growth further significant; Latin America, Middle East, Africa, and Southeast Asia delivered better growth.
- Generic exports mixed: Including Institutions, generic exports grew 14%; excluding Institutions, growth was ~6% for the quarter.
- ROW milestone: First time crossing INR 500 crores in ROW market business in the current year; management expects ROW markets to continue growing around 15% to 16%, 17%.
- European business: Already growing ~20% in the current year; UK business expected to grow very well next year as the base effect of Bristol a year back will not be there.
- Onyx UK: Remains a good profitable company; profitability came down a little this year because of significant expansion, but it remains profitable overall.
Dewas Plant: The Zero-Revenue Cost Center
- Current status: The Dewas plant is in validation mode only; all costs (depreciation, people, testing, energy) are debited to the P&L with no top-line contribution.
- Validation pipeline: 11 to 12 product validations are lined up; each validation takes around two to three months.
- Filing timeline: Filings should start somewhere in early next year (beginning), after six-month stability studies and dossier compilations.
- Inspection and approval timeline: Management hopes that next year, at least a few inspections should start happening and approvals should start coming; some regulators may come early, some late.
- Domestic sales possible sooner: Some production from Dewas may happen and be sold in domestic markets where approvals (licenses, GMPs) are already in place.
- No revenue factored into projections: Currently, no business increase from the Dewas plant is factored into projections; if commercial operations start mid-year, at least some recovery of expenditure will begin.
Ajit Kumar: "No, so, current year, even Dewas plant all costs are debited to P&L account, there are no business. It will — all cost only because till the time we start filing and getting approval, depreciations and all your people cost, testing costs, all the energy cost, everything is debited to P&L account, and there are no top line coming from that plant. So it's only validation mode. So it's a one-year 1.5 years, that pain is there in pharma industry everywhere."
Regulatory and Pipeline Updates
- US FDA remediation complete: The GMP department has given final clearance in writing six months ago, stating they need nothing further; all remediation issues are "things of past"; the company is awaiting re-inspection scheduling and sending reminders, but the FDA does not disclose when they will come.
- Sartan issues fully resolved: All approvals for Valsartan and Losartan received; all work required on impurities is done; no more such issues remain.
- Nagpur site cleared: About two months before the call, the Environment Ministry in Delhi accepted the Maharashtra Government's recommendation that the site does not need forest clearance; the process took almost 1–1.5 years.
- Flow chemistry at Nagpur: The company is working on flow chemistry projects to be placed at Nagpur.
- Product transfer to Aurangabad: Due to Nagpur delays, one product that was to be transferred to Nagpur is being placed at Aurangabad; that plant is already operational.
- Biotech project: A biotech project is coming up in MP with ~INR 150 crores investment, to be commissioned next year; almost five products in the pipeline, two in clinical stage; the focus is on global developed markets, not India.
- Trophic Wellness: The nutraceutical marketing company (55% stake) is doing well and is profitable.
- Bayshore US: Bayshore is a concern; it is awaiting FDA clearance so it can market products; until then, performance is constrained.
- US small API/contract research company: Losses have reduced significantly this year; projects have started coming in after COVID-related delays; expected to do better in time.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 FY23 revenue growth | Almost around 10% to 12% range | Q4 FY23 |
| FY24 EBITDA margin | Around 21% | FY24 |
| Margin trajectory beyond FY24 | Margins to rise ~1% every year for three years, with no significant field force expansion | FY25–FY27 |
| API business full-year FY23 | 7–8% nine-month decline to be entirely covered; full year more or less flat vs. last year (~INR 1,311 cr) | FY23 |
| API gross margin normalization | Everything back to normal from Q1 FY24 as high-cost KSM inventory clears | Q1 FY24 |
| Export Branded Formulation full-year growth | In excess of 17–18% | FY23 |
| ROW market growth | Continue to grow around 15–17% | Ongoing |
| Dewas plant filings | Filings to start in early next year (beginning) after validations and six-month stability | Early FY25 |
| Overall company growth FY24 | Almost around 12–13% | FY24 |
| API growth FY24 | Around 10%; faster growth only after Dewas capacities are available and approved | FY24 |
| Promotional spend | To remain at the same absolute level next year, creating operating leverage as revenue grows | FY24 |
| Capex | INR 400–500 crores total, including routine maintenance capex (depreciation ~INR 200 cr) | FY24–25 |
| Biotech plant commissioning | To be commissioned next year; ~INR 150 cr investment | FY24 |
| NLEM price increase | 12% WPI-based price increase effective 1 April; net NLEM impact ~3–3.5% after increase | April 2023 |
| Tax rate | Likely in the range of 29–30% | Ongoing |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹702 cr (Domestic Formulation), +9% YoY from ₹645 cr |
| Domestic Formulation 9M growth | ~10% |
| Export Branded Formulation revenue | ₹125 cr, +17% YoY from ₹109 cr |
| Export Branded Formulation 9M growth | ~11% |
| Generic export growth (incl. Institutions) | 14% |
| Generic export growth (excl. Institutions) | ~6% |
| API revenue | ₹322 cr, +4% YoY from ₹310 cr |
| API 9M decline | ~7%, from ₹1,084 cr to ~₹1,004 cr |
| Material cost to total income ratio | 34.13%, vs 32.46% in Q3 FY22, +1.67 ppt |
| 9M material cost ratio | ~33.88%, marginally higher than 33% in FY22 |
| Forex loss (other expenses) | ~₹16 cr loss, vs ~₹10 cr gain in Q3 FY22 |
| EBITDA margin guidance (FY24) | ~21% |
| NLEM price reduction impact (annual) | ~₹70 cr reduction |
| NLEM contribution to domestic business | 17% as of January-end |
| Scheduled Formulation price reduction | ~15% |
| Wholesale price increase expected (April) | ~12% |
| Net NLEM impact for FY24 | ~3% to 3.5% reduction |
| MR additions in current year | ~1,500 |
| Promotional cost increase (9M) | ~40% to 45% vs last year |
| Energy cost increase (current year) | ~45% |
| Travel cost increase | ~doubled |
| Manpower cost increase (reported) | 13%, excluding incentive is higher |
| Domestic market share (IQVIA, 2022) | 1.86%, up from 1.77% in 2021 |
| IQVIA rank | 17th company, up from 21st |
| Acute therapies rank | 13th, three-rank gain |
| Chronic segment rank | 18th, one-rank gain |
| Rheumatoid Arthritis & Osteoarthritis growth | 15% |
| Cardiovascular & Anti-diabetics growth | ~2% |
| Antimalarials decline (quarter) | ~36% |
| Antimalarials decline (9M) | ~37% |
| CNS business growth | ~18% |
| Derma growth | ~18% |
| Ophthalmology portfolio growth | ~17% |
| Neuro growth | ~13% |
| Cough and Cold growth | ~10% |
| Antibacterials 9M revenue | ₹134 cr, vs ₹143 cr in FY22 |
| ROW market business (full year) | Crossing ₹500 cr for the first time |
| ROW market growth expectation | ~15% to 17% |
| API business FY24 growth expectation | ~10% |
| Overall company FY24 growth expectation | ~12% to 13% |
| Tax rate expectation | ~29% to 30% |
| Capex guidance (FY24–25, per year) | ₹400 cr to ₹500 cr, incl. maintenance |
| Biotech project capex | ~₹150 cr, commissioning next year |
| Biotech R&D spend (current year) | ~₹20 cr to ₹25 cr |
| Onyx UK expected revenue (current year) | ~GBP 1.4 cr to 1.5 cr, ~27% margin |
| European business growth (current year) | ~20% |
| FY23 YTD net forex loss | ~₹41.9 cr |
| Artemisinin price history range | $140 to $800 |